<DOC>
	<DOC>NCT01563458</DOC>
	<brief_summary>This trial is conducted in Europe, North America and Oceania. The aim of this trial is to evaluate the haemostatic efficacy of activated recombinant human factor VII in subjects undergoing orthotopic liver transplantation surgery.</brief_summary>
	<brief_title>Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Scheduled to undergo orthotopic liver transplantation Liver disease classified as ChildTurcotte (Pughs modification) score B or C Previous liver transplantation Scheduled multiorgan transplantation Scheduled for living related donor transplantation Present renal insufficiency requiring dialysis Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>